StockData
Quantum Genesis AI Corp. logo

Quantum Genesis AI Corp. (QGAI) stock

QGAIOTCIndustrial Organic ChemicalsFiscal year ends July 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Apr 30, 2026Last filing: 10-Q on Jun 11, 2026Score 0/30
$0.04−0.02 (-29.44%)

Close on Oct 19, 2026Market cap $1.43MP/E –Yield –

Quantum Genesis AI Corp. reported revenue of $0 for the twelve months to Apr 30, 2026. At the latest close the market valued the company at $1.43M.

Revenue
$0
TTM Q3 2026
Operating income
-$94.28K
TTM Q3 2026
EPS, diluted
-$0.12
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Apr 30, 2026

Valuation

Market cap
$1.43M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$4.44M
EPS, diluted
-$0.12
Book value per share
-$0.01
Diluted shares
35M

Trading

Previous close
$0.06
Open
$0.03
Day's range
$0.03 – $0.04
Volume
17,000
Average volume (20 days)
30,789

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodQGAIS&P 500DifferenceQGAI per yearS&P 500 per year
1 month-69.9%+0.6%−70.5 pts
3 months-49.2%+3.4%−52.6 pts
Year to date-98.6%+13.3%−111.9 pts
1 year-76.9%+16.6%−93.5 pts

Seven years at a glance

Fiscal years 2015 to 2025 and trailing twelve months, USD

Revenue

$0

Gross profit

–

Operating income

-$94.28K

Net income

-$4.44M

EPS, diluted

-$0.12

Free cash flow

–
Reported periodTrailing twelve months

About Quantum Genesis AI

Industrial Organic Chemicals

Quantumzyme Corp. is a biotransformation company that develops engineered enzymes focused on clean and green chemistry. The company designs biocatalysts to optimize active pharmaceutical ingredient production by replacing legacy chemical processes that use hazardous materials with environmentally sustainable alternatives. Its initial engineered enzyme product serves the pharmaceutical production of generic ibuprofen. Quantumzyme intends to license its technology to major pharmaceutical firms and active pharmaceutical ingredient manufacturers, while partnering with third-party organizations for large-scale manufacturing and distribution.

Company profile, executives and history

Quantum Genesis AI stock: common questions

What is Quantum Genesis AI's stock price?

QGAI closed at $0.04 on Oct 19, 2026, down 29.44% on the day.

What is Quantum Genesis AI's market cap?

Quantum Genesis AI was worth $1.43M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is QGAI's P/E ratio?

Quantum Genesis AI lost money over the twelve months to Apr 30, 2026 (diluted EPS -$0.12), so it has no meaningful P/E ratio.

How much revenue does Quantum Genesis AI make?

Quantum Genesis AI reported revenue of $0 for the twelve months to Apr 30, 2026.

Does Quantum Genesis AI pay a dividend?

No. Quantum Genesis AI has not paid a cash dividend over the last twelve months.

How has QGAI stock performed over the past year?

Including dividends, QGAI returned -76.9% over the past year, against +16.6% for the S&P 500.

Who are Quantum Genesis AI's competitors?

Companies most similar to Quantum Genesis AI by business, industry and size include CDXS, VGAS, BIOF, GWTI, WNDW.

See a number that looks wrong?